Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Acacia Pharma Group    ACPH   GB00BYWF9Y76

ACACIA PHARMA GROUP

(ACPH)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
2.9(c) 2.815(c) 2.86(c) 2.835(c) 2.81 Last
379 279 169 788 161 365 114 846 42 948 Volume
-4.29% -2.93% +1.60% -0.87% -0.88% Change
More quotes
Financials
Sales 2020 1,66 M 2,09 M 2,09 M
Net income 2020 -26,7 M -33,6 M -33,6 M
Net Debt 2020 26,1 M 32,8 M 32,8 M
P/E ratio 2020 -6,41x
Yield 2020 -
Sales 2021 22,8 M 28,7 M 28,7 M
Net income 2021 -31,3 M -39,4 M -39,4 M
Net Debt 2021 59,5 M 75,0 M 75,0 M
P/E ratio 2021 -5,52x
Yield 2021 -
Capitalization 172 M 218 M 217 M
EV / Sales 2020 120x
EV / Sales 2021 10,2x
Nbr of Employees 33
Free-Float 55,6%
More Financials
Company
Acacia Pharma Group Plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2019, the group had a portfolio of 2 products, including APD403 in phase II of clinical development (treatment of chemically induced nausea and vomiting) and Baremsys in pre-launch phase... 
More about the company
Latest news on ACACIA PHARMA GROUP
07/03Acacia Pharma Announces US FDA Approval of BYFAVO for injection for the Induc..
AQ
07/02ACACIA PHARMA : Announces US FDA Approval of BYFAVO™ (remimazolam) for inj..
PU
07/02ACACIA PHARMA : Announces US FDA Approval of BYFAVO™ (remimazolam) for inj..
AQ
06/04TR-1 : Standard form for notification of major holdings
AQ
06/01ACACIA PHARMA : Announces Debt for Equity Swap with Cosmo Pharmaceuticals
AQ
05/07ACACIA PHARMA : Issue of Equity on Exercise of Options/Vesting of Performance Sh..
AQ
04/09ACACIA PHARMA GROUP : Proxy Statments
CO
04/07ACACIA PHARMA : Alessandro Della Chà appointed as Director of Acacia Pharma Grou..
AQ
04/07ACACIA PHARMA : Results of Annual General Meeting
AQ
03/25COSMO PHARMACEUTICALS N : Acacia Pharma Group plc - Publication of Prospectus
AQ
03/24ACACIA PHARMA : Publication of Prospectus
AQ
03/23ACACIA PHARMA : Forthcoming 2020 Annual General Meeting – Change of Venue ..
AQ
03/17ACACIA PHARMA : Notice of Annual General Meeting
AQ
03/16ACACIA PHARMA GROUP PLC : Notice of Annual General Meeting
AQ
03/12ACACIA PHARMA : Announces Brief Extension of FDA Review Period for NDA for BYFAV..
AQ
More news
News in other languages on ACACIA PHARMA GROUP
07/03Acacia Pharma Announces US FDA Approval of BYFAVO for injection for the Induc..
07/03Cosmo recherché en Bourse après le feu vert de la FDA
07/03Cosmo-Aktien ziehen nach FDA-Zulassung für Sedativum Byfavo an
07/02COSMO : la FDA homologue le sédatif Byfavo
07/02ACACIA PHARMA : Announces US FDA Approval of BYFAVO™ (remimazolam) for inj..
More news
Chart ACACIA PHARMA GROUP
Duration : Period :
Acacia Pharma Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACACIA PHARMA GROUP
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price
Last Close Price 2,84 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Michael Bolinder Chief Executive Officer & Executive Director
Scott A. Byrd Chairman
Gary G. Gemignani Chief Financial Officer
Gabriel Fox Chief Medical Officer
John Robert Brown Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ACACIA PHARMA GROUP34.36%218
JOHNSON & JOHNSON-2.40%375 087
ROCHE HOLDING AG5.75%300 427
MERCK & CO., INC.-15.64%193 674
NOVARTIS AG-10.77%192 177
PFIZER, INC.-13.65%187 920